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measurements (GLM) to compare the groups. The trial was ap-
proved by the regional ethics committee in Norway, Norwegian
Medicines Agency and the Norwegian Data Inspectorate. All pro-
cedures conformed to the Declaration of Helsinki. The trial was
registered at http://www.clinicaltrials.gov under the identiﬁer NCT
0040407. The trial was initiated by Ulleval University Hospital and
ﬁnanced by the Norwegian LBP organization and not producer
ﬁnanced.
Results: This is an interim analysis only. Mean age of the patients
(n=250) was 48,5 years. 48.4% were women. Lost to follow up at 6
months was 18 and equal in both groups. GS was not signiﬁcantly
better than placebo in reducing RMDQ score by 3 points. Repeated
measurements (GLM) demonstrated no difference between the
glucosamine- and the placebo-group. None of the secondary
outcomes (NPS, EQ-5D etc) demonstrated any difference between
the groups. RMDQ, NPS, LBP duration, race, age, sex, weight,
height, BMI, EQ-5D and HSCL-25 were similar in both groups at
baseline. No changes in fasting plasma glucose and cholesterol
levels were observed post trial participation in either treatment
arm. Adverse events were mild, rare and equally distributed among
the two groups.
Conclusions: Interim results show that daily intake of glu-
cosamine sulfate for 6 months was not effective in reducing low
back pain measured with RMDQ.
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Purpose: The goal was to study the effect of a lateral-wedged
insole compared to valgus bracing in patients with symptomatic
medial compartmental knee osteoarthritis (OA).
Methods: Consecutive patients with symptomatic medial com-
partmental knee OA who visited the orthopaedic outpatient de-
partment of a university medical center were eligible for inclusion.
Patients with symptoms not related to medial compartmental OA,
younger than 35 years of age, an insufﬁcient command of the
Dutch language, or no varus malalignment were excluded. The
degree of knee alignment (hip-knee-ankle angle) was assessed
on a digitalized whole leg radiograph in standing position. After
written informed consent patients were randomly assigned to ei-
ther an intervention group comprising a shoe inserted leather sole
with a lateral-wedged cork elevation of 10 millimeters (6° wedge),
or to a control group comprising a commercially available valgus
knee brace. The allocation of treatment was concealed until after
the participants were included and baseline measurements were
executed. One assessor performed all baseline and 6 months
follow-up measurements.Primary outcome measure was change
in pain severity (VAS). Besides knee function scores (HSS, KSS,
WOMAC), percentage responders, varus alignment correction in
the frontal plane using the hip-knee-ankle angle, and compliance
to the intervention. Responders to the intervention were deﬁned
as having an improvement of ≥ 20% compared to the baseline
score for pain and function.
Results: Between January 2006 and September 2007, 91 con-
secutive patients were included and randomized (45 insole group;
46 brace group). Pain severity scores improved more in the insole
group compared with the bracing group for VAS (-.09; 95% CI:
-1.31; 1.13; effect size 0.04) and WOMAC pain score (.13; 95%CI:
-9.43; 9.18; effect size 0.004). Knee function was better for the
insole group for HSS score (1.69; 95% CI: -3.17; 6.55, effect size
0.16), KSS score (5.47; 95% CI: -12.48; 1.53, effect size 0.34),
and WOMAC function score (1.43; 95% CI: -9.39; 6.53, effect
size 0.07). There were no signiﬁcant differences in percentages
of responders between the insole and the brace groups (27% vs
25%, respectively).Both intervention had no impact on the varus
malalignment. At 6 months 71% of patients in the insole group
complied with the intervention, which was signiﬁcantly (p = 0.015)
higher compared to 45% for the brace group.
Conclusions: We found no differences in effectiveness of both a
6° lateral-wedged leather shoe inlay and a commercially available
valgus brace in the treatment of patients with symptomatic medial
OA of the knee joint after 6 months. According to the OMERACT-
OARSI set of responder criteria for clinical trials in OA, however,
only one fourth of all patients beneﬁted from either the insole or
brace intervention.
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Purpose: Naproxcinod is a Cyclooxygenase Inhibiting Nitric Ox-
ide Donator (CINOD) under development for the relief of signs
and symptoms of OA. Naproxcinod exerts its activity through its
two primary metabolites: naproxen and the NO donating moiety.
In previous clinical trials, naproxcinod has shown similar anti-
inﬂammatory and analgesic efﬁcacy to conventional NSAIDs, and
an improved BP safety and tolerability proﬁle, likely due to its NO
donation.
The primary objective of the study was to show that naproxcinod
375 mg bid and 750 mg bid were superior to placebo in relieving
signs and symptoms in subjects with OA of the knee after 13
weeks of treatment.
Methods: In this placebo 13-week and naproxen 26-week con-
trolled study, men and women 40+ years old with a diagnosis
of primary OA of the knee meeting ACR criteria and experienc-
ing a ﬂare of pain at baseline after discontinuation of previous
anti-inﬂammatory or acetaminophen treatments were randomized
(1:1:1:1) to either naproxcinod 375 mg or 750 mg bid, naproxen
500 mg bid or placebo bid. The three co-primary efﬁcacy variables
were the mean change from Baseline at Week 13 in WOMAC™
pain and function subscale scores and subject’s global assess-
ment of disease status. The superiority analysis of naproxcinod
over placebo was the primary efﬁcacy analysis.
The analysis of each primary efﬁcacy variable was based on
an analysis of covariance (ANCOVA) with treatment group as
factor, and baseline value as covariate. The primary efﬁcacy
analysis was performed using the Intent-to-Treat (ITT) population
(all randomized subjects) and was performed on as-randomized
basis.
Results: A total of 1011 subjects from 129 US centers were
included in the ITT population. 71.0% of subjects were female,
78.9% were Caucasian. The mean age was 59.8 years and mean
BMI 33.8 kg/m2. A total of 766 (75.8%) subjects completed the 13
week study period.
Both doses of naproxcinod (375 mg bid and 750 mg bid) demon-
